Ocuphire Pharma Investor Presentation Deck
Percent of Subjects with Binocular Improvement or Worsening in DRSS at Wk 24
APX3330 Demonstrated Statistical Efficacy on the Pre-Specified, Planned Phase 3 Registration Endpoint
Percent of Subjects With Binocular Improvement or Worsening in DRSS
of ≥ 1, ≥ 2, ≥ 3, and ≥ 4 Steps From Baseline (mITT-LOCF)
Percent of Subjects (%)
40%
35%
€30%
25%
20%
15%
10%
5%
0%
Ocuphire
8%
0%
DRSS Worsening
p<0.05
16%
0%
> 4 Steps ≥ 3 Steps
Worsening
Worsening
ZETA-1 Clinical Trial; p values shown if p<0.20
Table 14.2.2.7, March 2023
18%
11%
36%
34%
≥ 2 Steps ≥ 1 Steps
Worsening Worsening
Placebo (n=50)
36%
34%
No Change
32%
28%
DRSS Improvement
APX3330 (n=47)
20%
17%
6%
11%
p=0.18
2%
9%
≥ 2 Step
≥ 3 Step
≥ 4 Step
≥ 1 Step
Improvement Improvement Improvement Improvement
24View entire presentation